AAAAAA

   
Results: 1-15 |
Results: 15
Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma
Authors: Goy, A Gilles, F Remache, Y Filippa, D Portlock, CS Jhanwar, SC Zelenetz, AD
Citation: A. Goy et al., Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma, LEUK LYMPH, 40(3-4), 2001, pp. 419-423
Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas
Authors: Chen, WY Palanisamy, N Schmidt, H Teruya-Feldstein, J Jhanwar, SC Zelenetz, AD Houldsworth, J Chaganti, RSK
Citation: Wy. Chen et al., Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas, ONCOGENE, 20(52), 2001, pp. 7686-7693
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Authors: Kaminski, MS Zelenetz, AD Press, OW Saleh, M Leonard, J Fehrenbacher, L Lister, TA Stagg, RJ Tidmarsh, GF Kroll, S Wahl, RL Knox, SJ Vose, JM
Citation: Ms. Kaminski et al., Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 19(19), 2001, pp. 3918-3928
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol
Authors: Noy, A Verma, R Glenn, M Maslak, P Rahman, ZU Keenan, JR Weiss, M Filippa, D Zelenetz, AD
Citation: A. Noy et al., Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol, BLOOD, 97(7), 2001, pp. 1929-1936
A 2-step comprehensive high-dose chemoradiotherapy second-line program forrelapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
Authors: Moskowitz, CH Nimer, SD Zelenetz, AD Trippett, T Hedrick, EE Filippa, D Louie, D Gonzales, M Walits, J Coady-Lyons, N Qin, J Frank, R Bertino, JR Coy, A Noy, A O'Brien, JP Straus, D Portlock, CS Yahalom, J
Citation: Ch. Moskowitz et al., A 2-step comprehensive high-dose chemoradiotherapy second-line program forrelapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model, BLOOD, 97(3), 2001, pp. 616-623
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy
Authors: Donnelly, GB Glassman, J Long, C Torres, P Straus, DJ O'Brien, JP Bertino, J Moskowitz, CH Zelenetz, AD Portlock, CS
Citation: Gb. Donnelly et al., Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy, LEUK LYMPH, 39(1-2), 2000, pp. 67-75
A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22
Authors: Gilles, F Glenn, M Goy, A Remache, Y Zelenetz, AD
Citation: F. Gilles et al., A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22, EUR J HAEMA, 64(2), 2000, pp. 104-113
Cloning and characterization of a Golgin-related gene from the large-scalepolymorphism linked to the PML gene
Authors: Gilles, F Goy, A Remache, Y Manova, K Zelenetz, AD
Citation: F. Gilles et al., Cloning and characterization of a Golgin-related gene from the large-scalepolymorphism linked to the PML gene, GENOMICS, 70(3), 2000, pp. 364-374
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
Authors: Vose, JM Wahl, RL Saleh, M Rohatiner, AZ Knox, SJ Radford, JA Zelenetz, AD Tidmarsh, GF Stagg, RJ Kaminski, MS
Citation: Jm. Vose et al., Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 18(6), 2000, pp. 1316-1323
Physical linkage of the lysyl oxidase-like (LOXL1)gene to the PML gene on human chromosome 15q22
Authors: Goy, A Gilles, F Remache, Y Zelenetz, AD
Citation: A. Goy et al., Physical linkage of the lysyl oxidase-like (LOXL1)gene to the PML gene on human chromosome 15q22, CYTOG C GEN, 88(1-2), 2000, pp. 22-24
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
Authors: Kewalramani, T Zelenetz, AD Hedrick, EE Donnelly, GB Hunte, S Priovolos, AC Qin, J Lyons, NC Yahalom, J Nimer, SD Moskowitz, CH
Citation: T. Kewalramani et al., High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis, BLOOD, 96(7), 2000, pp. 2399-2404
MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma
Authors: Gilles, F Goy, A Remache, Y Shue, P Zelenetz, AD
Citation: F. Gilles et al., MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma, BLOOD, 95(9), 2000, pp. 2930-2936
Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
Authors: Moskowitz, CH Bertino, JR Glassman, JR Hedrick, EE Hunte, S Coady-Lyons, N Agus, DB Goy, A Jurcic, J Noy, A O'Brien, J Portlock, CS Straus, DS Childs, B Frank, R Yahalom, J Filippa, D Louie, D Nimer, SD Zelenetz, AD
Citation: Ch. Moskowitz et al., Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3776-3785
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
Authors: Moskowitz, CH Nimer, SD Glassman, JR Portlock, CS Yahalom, J Straus, DJ O'Brien, JP Elkin, N Bertino, JR Zelenetz, AD
Citation: Ch. Moskowitz et al., The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma, BONE MAR TR, 23(6), 1999, pp. 561-567
The W-sh, W-57, and Ph Kit expression mutations define tissue-specific control elements located between-23 and-154 kb upstream of Kit
Authors: Berrozpe, G Timokhina, I Yukl, S Tajima, Y Ono, M Zelenetz, AD Besmer, P
Citation: G. Berrozpe et al., The W-sh, W-57, and Ph Kit expression mutations define tissue-specific control elements located between-23 and-154 kb upstream of Kit, BLOOD, 94(8), 1999, pp. 2658-2666
Risultati: 1-15 |